Abivax Responds to Acquisition Speculations
By Sabrina Valle
Market Reaction to Rumors
On January 20, in a statement that echoed through financial markets, Abivax CEO Marc de Garidel dismissed ongoing acquisition rumors involving pharmaceutical giant Eli Lilly as mere “noise.” He underscored that these speculations, alongside reports regarding a review by French authorities, were not reflective of the realities governing foreign investment regulation in France. This clarification comes amidst intense interest in Abivax’s fluctuating stock performance.
The Surge in Stock Performance
Abivax shares experienced a remarkable surge of over 2,000% from July to December, reaching a peak of 145 euros per share on December 26. This spike, however, was followed by a retracement to 101 euros after the French government publicly debunked the acquisition rumors. Much of this dramatic increase was driven by positive clinical results for Obefazimod, Abivax’s promising drug targeting inflammatory bowel disease, announced on July 22.
Insights from the CEO on Acquisition Discussions
De Garidel addressed investors by rejecting claims that Eli Lilly had engaged in discussions with the French government concerning a potential acquisition of Abivax. He stated, “There was no discussion about acquiring Abivax. If there was a conversation, it would be illegal.” His comments aimed to quell mounting investor anxiety and speculation around the company’s future amidst these unfounded reports.
Context of the Investment Climate
De Garidel insisted that the narrative surrounding the alleged acquisition is a distraction from Abivax’s regulatory process. He explained that any potential conversations between acquiring companies and the French Finance Ministry would only take place after a formal transaction announcement. “To suggest otherwise does not reflect how our government processes work,” he noted. His insights underline the importance of adhering to both legal and procedural norms in acquisition scenarios.
Financial Stability and Future Prospects
While Abivax is well-capitalized, with sufficient liquidity to fund its projects until the fourth quarter of 2027, the CEO admitted that additional capital would be necessary to reach profitability. At the recent JP Morgan Healthcare conference, the company sought to connect with high-quality investors, emphasizing its ongoing commitment to growth in the biotechnology sector.
Analyst Perspectives and Market Potential
Market analysts, including those from Morgan Stanley and JP Morgan, have revised their price targets for Abivax, estimating values between $140 and $145. This optimism is largely attributed to the commercial potential of Obefazimod, which could serve as a gold standard treatment for ulcerative colitis in a market projected to surpass $25 billion by 2030. Such projections position Abivax as an attractive acquisition target within the pharmaceutical landscape.
Conclusion: Looking Ahead
As Abivax prepares to release critical phase 3 data for Obefazimod by the end of June, the biotech firm remains committed to enhancing its strategic value. Success in these trials could significantly mitigate investment risks and bolster its appeal to potential acquirers. Meanwhile, Eli Lilly has refrained from commenting on any acquisition speculations, keeping the market guessing about future developments. Abivax’s journey continues as it navigates the intersection of innovation, investment, and regulation.